First Time Loading...

CRISPR Therapeutics AG
NASDAQ:CRSP

Watchlist Manager
CRISPR Therapeutics AG Logo
CRISPR Therapeutics AG
NASDAQ:CRSP
Watchlist
Price: 53.91 USD 0.34% Market Closed
Updated: Apr 27, 2024

Intrinsic Value

CRSP's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

CRISPR Therapeutics AG operates as a gene editing company. [ Read More ]

The intrinsic value of one CRSP stock under the Base Case scenario is 162.33 USD. Compared to the current market price of 53.91 USD, CRISPR Therapeutics AG is Undervalued by 67%.

Key Points:
CRSP Intrinsic Value
Base Case
162.33 USD
Undervaluation 67%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
CRISPR Therapeutics AG

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling CRSP stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
CRISPR Therapeutics AG

Provide an overview of the primary business activities
of CRISPR Therapeutics AG.

What unique competitive advantages
does CRISPR Therapeutics AG hold over its rivals?

What risks and challenges
does CRISPR Therapeutics AG face in the near future?

Has there been any significant insider trading activity
in CRISPR Therapeutics AG recently?

What significant events have occurred
in CRISPR Therapeutics AG over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for CRISPR Therapeutics AG.

Provide P/S
for CRISPR Therapeutics AG.

Provide P/E
for CRISPR Therapeutics AG.

Provide P/OCF
for CRISPR Therapeutics AG.

Provide P/FCFE
for CRISPR Therapeutics AG.

Provide P/B
for CRISPR Therapeutics AG.

Provide EV/S
for CRISPR Therapeutics AG.

Provide EV/GP
for CRISPR Therapeutics AG.

Provide EV/EBITDA
for CRISPR Therapeutics AG.

Provide EV/EBIT
for CRISPR Therapeutics AG.

Provide EV/OCF
for CRISPR Therapeutics AG.

Provide EV/FCFF
for CRISPR Therapeutics AG.

Provide EV/IC
for CRISPR Therapeutics AG.

Show me price targets
for CRISPR Therapeutics AG made by professional analysts.

What are the Revenue projections
for CRISPR Therapeutics AG?

How accurate were the past Revenue estimates
for CRISPR Therapeutics AG?

What are the Net Income projections
for CRISPR Therapeutics AG?

How accurate were the past Net Income estimates
for CRISPR Therapeutics AG?

What are the EPS projections
for CRISPR Therapeutics AG?

How accurate were the past EPS estimates
for CRISPR Therapeutics AG?

What are the EBIT projections
for CRISPR Therapeutics AG?

How accurate were the past EBIT estimates
for CRISPR Therapeutics AG?

Compare the revenue forecasts
for CRISPR Therapeutics AG with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of CRISPR Therapeutics AG and its key competitors using the latest financial data.

Compare historical revenue growth rates
of CRISPR Therapeutics AG against its competitors.

Analyze the profit margins
(gross, operating, and net) of CRISPR Therapeutics AG compared to its peers.

Compare the P/E ratios
of CRISPR Therapeutics AG against its peers.

Discuss the investment returns and shareholder value creation
comparing CRISPR Therapeutics AG with its peers.

Analyze the financial leverage
of CRISPR Therapeutics AG compared to its main competitors.

Show all profitability ratios
for CRISPR Therapeutics AG.

Provide ROE
for CRISPR Therapeutics AG.

Provide ROA
for CRISPR Therapeutics AG.

Provide ROIC
for CRISPR Therapeutics AG.

Provide ROCE
for CRISPR Therapeutics AG.

Provide Gross Margin
for CRISPR Therapeutics AG.

Provide Operating Margin
for CRISPR Therapeutics AG.

Provide Net Margin
for CRISPR Therapeutics AG.

Provide FCF Margin
for CRISPR Therapeutics AG.

Show all solvency ratios
for CRISPR Therapeutics AG.

Provide D/E Ratio
for CRISPR Therapeutics AG.

Provide D/A Ratio
for CRISPR Therapeutics AG.

Provide Interest Coverage Ratio
for CRISPR Therapeutics AG.

Provide Altman Z-Score Ratio
for CRISPR Therapeutics AG.

Provide Quick Ratio
for CRISPR Therapeutics AG.

Provide Current Ratio
for CRISPR Therapeutics AG.

Provide Cash Ratio
for CRISPR Therapeutics AG.

What is the historical Revenue growth
over the last 5 years for CRISPR Therapeutics AG?

What is the historical Net Income growth
over the last 5 years for CRISPR Therapeutics AG?

What is the current Free Cash Flow
of CRISPR Therapeutics AG?

Discuss the annual earnings per share (EPS)
trend over the past five years for CRISPR Therapeutics AG.

Financials

Balance Sheet Decomposition
CRISPR Therapeutics AG

Current Assets 1.9B
Cash & Short-Term Investments 1.7B
Receivables 200m
Other Current Assets 14.4m
Non-Current Assets 321.5m
Long-Term Investments 2m
PP&E 305.9m
Intangibles 16k
Other Non-Current Assets 13.6m
Current Liabilities 108.8m
Accounts Payable 38.1m
Accrued Liabilities 61m
Other Current Liabilities 9.7m
Non-Current Liabilities 238m
Other Non-Current Liabilities 238m
Efficiency

Earnings Waterfall
CRISPR Therapeutics AG

Revenue
371.2m USD
Operating Expenses
-593.7m USD
Operating Income
-222.5m USD
Other Expenses
68.9m USD
Net Income
-153.6m USD

Free Cash Flow Analysis
CRISPR Therapeutics AG

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

CRSP Profitability Score
Profitability Due Diligence

CRISPR Therapeutics AG's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
ROE is Increasing
36/100
Profitability
Score

CRISPR Therapeutics AG's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

CRSP Solvency Score
Solvency Due Diligence

CRISPR Therapeutics AG's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

CRISPR Therapeutics AG's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CRSP Price Targets Summary
CRISPR Therapeutics AG

Wall Street analysts forecast CRSP stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CRSP is 87.55 USD with a low forecast of 30.3 USD and a high forecast of 208.95 USD.

Lowest
Price Target
30.3 USD
44% Downside
Average
Price Target
87.55 USD
62% Upside
Highest
Price Target
208.95 USD
288% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

CRSP Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

CRSP Price
CRISPR Therapeutics AG

1M 1M
-23%
6M 6M
+39%
1Y 1Y
+10%
3Y 3Y
-59%
5Y 5Y
+34%
10Y 10Y
+283%
Annual Price Range
53.91
52w Low
38.62
52w High
89.12
Price Metrics
Average Annual Return 28.88%
Standard Deviation of Annual Returns 102.29%
Max Drawdown -82%
Shares Statistics
Market Capitalization 4.3B USD
Shares Outstanding 80 276 000
Percentage of Shares Shorted 18.63%

CRSP Return Decomposition
Main factors of price return

What is price return decomposition?

CRSP News

Other Videos

Last Important Events
CRISPR Therapeutics AG

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
CRISPR Therapeutics AG

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

CRISPR Therapeutics AG Logo
CRISPR Therapeutics AG

Country

Switzerland

Industry

Biotechnology

Market Cap

4.3B USD

Dividend Yield

0%

Description

CRISPR Therapeutics AG operates as a gene editing company. The company is headquartered in Zug, Zug and currently employs 473 full-time employees. The company focuses on the development of transformative gene-based medicines for serious diseases. The firm develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform, which allows for precise directed changes to genomic deoxyribonucleic acid (DNA). The firm has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine and rare diseases. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The firm has business operations in London and the United Kingdom, as well as research and development operations in the United States.

Contact

ZUG
Zug
Baarerstrasse 14
+41415613277.0
http://www.crisprtx.com/about-us/contact

IPO

-

Employees

473

Officers

CEO & Chairman
Dr. Samarth Kulkarni Ph.D.
General Counsel & Secretary
Mr. James R. Kasinger
Founder
Mr. Shaun Foy
Co-Founder & Scientific Advisory Board Member
Dr. Emmanuelle Marie Charpentier
Scientific Founder
Dr. Chad A. Cowan Ph.D.
Scientific Founder & Advisory Board Member
Dr. Daniel G. Anderson Ph.D.
Show More
Chief Financial Officer
Dr. Raju Yashaswi Prasad Ph.D.
Head of Technical Operations
Mr. Stephen Kennedy
Show Less

See Also

Discover More
What is the Intrinsic Value of one CRSP stock?

The intrinsic value of one CRSP stock under the Base Case scenario is 162.33 USD.

Is CRSP stock undervalued or overvalued?

Compared to the current market price of 53.91 USD, CRISPR Therapeutics AG is Undervalued by 67%.